Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 29 articles: HTML format

Single Articles

February 2023
1. WENZEL HHB, Hardie AN, Moncada-Torres A, Hogdall CK, et al
   A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
   Eur J Cancer. 2023;185:61-68.
   PubMed     Abstract available
   
   
   
2. WANG J, Cai L, Song Y, Sun T, et al
   Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
   Eur J Cancer. 2023;184:73-82.
   PubMed     Abstract available
   
   
   January 2023
3. HERZOG TJ, Vergote I, Gomella LG, Milenkova T, et al
   Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
   Eur J Cancer. 2023;179:136-146.
   PubMed     Abstract available
   
   
   December 2022
4. CUEVA JF, Palacio I, Churruca C, Herrero A, et al
   Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
   Eur J Cancer. 2022;182:3-14.
   PubMed     Abstract available
   
   
   
5. PANOUTSOPOULOU K, Magkou P, Dreyer T, Dorn J, et al
   tRNA-derived small RNA 3'U-tRF(ValCAC) promotes tumour migration and early progression in ovarian cancer.
   Eur J Cancer. 2022;180:134-145.
   PubMed     Abstract available
   
   
   
6. SABATIER R, Rousseau F, Joly F, Cropet C, et al
   Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged >/=65 years from the PAOLA-1/ENGOT-ov25 trial.
   Eur J Cancer. 2022;181:42-52.
   PubMed     Abstract available
   
   
   September 2022
7. XU B, Hu X, Li W, Sun T, et al
   Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
   Eur J Cancer. 2022;175:236-245.
   PubMed     Abstract available
   
   
   
8. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
   Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
   Eur J Cancer. 2022;175:180-186.
   PubMed     Abstract available
   
   
   
9. GONZALEZ-MARTIN A, Desauw C, Heitz F, Cropet C, et al
   Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
   Eur J Cancer. 2022;174:221-231.
   PubMed     Abstract available
   
   
   August 2022
10. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    PubMed     Abstract available
    
    
    July 2022
11. OAKNIN A, Monk BJ, Vergote I, Cristina de Melo A, et al
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer. 2022 Jul 31. pii: S0959-8049(22)00160.
    PubMed     Abstract available
    
    
    
12. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available
    
    
    
13. PASHANKAR F, Hanley K, Lockley M, Stoneham S, et al
    Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
    Eur J Cancer. 2022;173:59-70.
    PubMed     Abstract available
    
    
    June 2022
14. PESENTI C, Beltrame L, Velle A, Fruscio R, et al
    Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
    Eur J Cancer. 2022;171:85-95.
    PubMed     Abstract available
    
    
    
15. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    PubMed    
    
    
    
16. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available
    
    
    May 2022
17. SIMON S, Francis KE, Dalrymple JE, Gebski V, et al
    Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2022;170:169-178.
    PubMed     Abstract available
    
    
    
18. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available
    
    
    
19. PAULET L, Trecourt A, Leary A, Peron J, et al
    Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Eur J Cancer. 2022;166:87-99.
    PubMed     Abstract available
    
    
    April 2022
20. AKESSON A, Adok C, Dahm-Kahler P
    Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
    Eur J Cancer. 2022;169:54-63.
    PubMed     Abstract available
    
    
    
21. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available
    
    
    March 2022
22. CARTER TJ, George C, Harwood C, Nathan P, et al
    Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.
    Eur J Cancer. 2022;166:240-253.
    PubMed     Abstract available
    
    
    December 2021
23. DITTO A, De Cecco L, Paolini B, Alberti P, et al
    Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Eur J Cancer. 2021;161:55-63.
    PubMed     Abstract available
    
    
    
24. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    PubMed     Abstract available
    
    
    October 2021
25. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Eur J Cancer. 2021;158:111-122.
    PubMed     Abstract available
    
    
    September 2021
26. VERGOTE I, Ray-Coquard I, Anderson DM, Cantuaria G, et al
    Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Eur J Cancer. 2021;157:415-423.
    PubMed     Abstract available
    
    
    
27. KANTIDAKIS G, Litiere S, Neven A, Vinches M, et al
    Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sar
    Eur J Cancer. 2021;154:253-268.
    PubMed     Abstract available
    
    
    
28. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    PubMed     Abstract available
    
    
    March 2021
29. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: